Effective for dates of service on and after July 14, 2019, the following updates will apply to the AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline.

 

  • Prostate Cancer: Added criteria for the appropriate use of PET-CT with the radiotracers Axumin and 11-Choline, establishing the position of this test in the care continuum for prostate cancer primarily related to biochemical recurrence

 

  • Neuroendocrine Tumors: Added criteria for the appropriate use of PET-CT with the radiotracer DOTA-TATE, establishing the position of this test in the care continuum for neuroendocrine tumors


As a reminder, ordering and servicing providers may submit pre-certification requests to AIM in one of several ways:

  • Access AIM ProviderPortalSM directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
  • Call the AIM Contact Center toll-free number: 877-291-0366, Monday - Friday, 7:00 a.m. - 5:00 p.m. PT.

 

For questions related to guideline updates, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com.  To access and download a copy of the current guidelines, go to:  http://www.aimspecialtyhealth.com/ClinicalGuidelines.html.



Featured In:
August 2019 Anthem Provider News and Important Updates - Nevada